

May 1, 2007



Pressure BioSciences, Inc. to Unveil New, Lightweight, Compressed Air Driven Barocyler Instrument at BIO 2007

WEST BRIDGEWATER, Mass., May 1 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO) today announced that it will unveil a patent-pending, lightweight, compressed air driven pressure cycling instrument (Barocyler NEP2320) at the 2007 BIO International Convention, being held May 6-9 in Boston, Massachusetts. Approximately 20,000 attendees are expected at BIO 2007, an annual event generally considered one of the most important meetings of the year for the international biotechnology industry.

The Barocyler NEP2320 is a smaller, more compact version of the Company's existing Barocyler instrument, the NEP3229. It offers a similar "look and feel" to the NEP3229, but has a system weight of approximately 75 verses 350 pounds, and processes one sample at a time, verses three for the NEP3229. The NEP2320 was originally designed to be a demonstration unit for the larger NEP3229; however, the Company's market research suggests that there may be a niche in genomics and proteomics research laboratories for a Barocyler instrument with a lower sample throughput and a lower price, but with many of the technical capabilities of the higher throughput Barocyler NEP3229.

Dr. Nathan P. Lawrence, Vice President of Marketing and Sales for PBI, said: "We developed the NEP2320 instrument to enable our sales force to more easily demonstrate the power of PCT to the growing number of scientists who have expressed a genuine interest in evaluating the PCT Sample Preparation System. However, after discussing this concept with prospective customers, it became apparent that this 'demonstration instrument' could be a powerful addition to our PCT product line, as it may address a new and important segment of our target market. Because it offers a significantly smaller footprint and reduced weight when compared to the NEP3229, we believe that the NEP2320 is well suited for the small research lab that demands safe and rapid, high quality sample preparation, but does not require the higher sample throughput of the Barocyler NEP3229. In addition, we believe that the NEP2320 could also make an excellent discovery tool in laboratories where bench space is at a premium. It is also very versatile, as it can run on lab supplied air, compressed gas, or a stand-alone compressor."

Mr. Richard T. Schumacher, Founder, President, and CEO of PBI, commented: "Our introduction of the Barocyler NEP2320 at BIO 2007, as both a demonstration instrument for the Barocyler NEP3229 and as a stand-alone PCT product, is a significant enhancement to our PCT commercialization plan, as announced on March 27, 2007. We believe that there are over 200,000 scientists throughout the world who can benefit from the PCT Sample Preparation System. The needs of these scientists vary on a number of factors, including sample throughput, available laboratory space for instrumentation, and budget limitations. We believe that our ability to offer two Barocyler models with comparable technical capabilities, but with distinctly different instrument features and price levels, will enable us to

expand the use of PCT at a faster pace to more and more life science companies."

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded, early-stage company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 5 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions (particularly enzymes), immunodiagnostics, and protein purification.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements include statements regarding the commercial launch of the Company's PCT product line; expected sales of Barocycler NEP3229 and Barocycler NEP2320 instruments; expected use of the portable Barocycler NEP2320 instrument as a demonstration unit and by small research laboratories; expected market for the Barocycler NEP3229 and the Barocycler NEP2320; the number of scientists who have expressed an interest in evaluating the PCT Sample Preparation System; the Company's expectation that the Barocycler NEP2320 will address certain needs of scientists and laboratories; the number of scientists who may benefit from the PCT Sample Preparation System; and the Company's expectations of the pace of adoption of the PCT Sample Preparation System. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: unforeseen technological difficulties that the Company may encounter in the development of the PCT technology and the PCT Sample Preparation System; the possibility that the Company's PCT technology may not be accepted by the commercial market as a needed improvement over current extraction methods and for other applications; the possibility that the Company may be unable to sell the Barocycler NEP3229 and the Barocycler NEP2320 instruments that it has ordered from its contract manufacturer; the possibility that due to unforeseen technological and commercial difficulties, the Company's design, development, and use of the Barocycler NEP2320 as a demonstration unit and as an alternative for the Barocycler NEP3229 may not be successful; and the other risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Visit us at our website <http://www.pressurebiosciences.com>

SOURCE Pressure BioSciences, Inc.